XML 53 R23.htm IDEA: XBRL DOCUMENT
v3.22.1

Stockholders’ Equity | 12 Months Ended
--- | ---
Jan. 01, 2022
Stockholders' Equity Note [Abstract] |
Stockholders’ Equity | Note 17: Stockholders’ Equity Common Stock: The Company's Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. During the fiscal year ended January 2, 2021, 104,798 shares of common stock were granted and issued in lieu of professional services at a fair value of approximately $351,000, which was recorded as share-based compensation expense. Additionally, the Company was amortizing the fair value of 223,214 common shares granted during September 2019, but not vested, in lieu of professional services at a fair value of $1.0 million. This agreement terminated during August 2020. As such, 71,607 common shares were returned to the Company and the related stock-based compensation expense was reversed. The Company recognized approximately $54,000 in share-based compensation expense related to these services, which was not reversed, during the year ended January 2, 2021. There were no similar transactions for the fiscal year ended January 1, 2022. As of January 1, 2022, and January 2, 2021, there were 2,827,410 and 1,829,982 shares, respectively, of common stock issued and outstanding. Equity Offering: On January 29, 2021, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”) for the sale by the Company in a registered direct offering (the “Offering”) of 571,428 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per share of Common Stock of $10.50. The Offering closed on February 2, 2021 with gross proceeds to the Company of approximately $6.0 million before deducting placement agent fees and other offering expenses. The Company is utilizing the net proceeds for general working capital. The Purchase Agreement contains customary representations, warranties and agreements by the Company and the Purchasers and customary indemnification rights and obligations of the parties. A.G.P./Alliance Global Partners acted as the sole placement agent (the “Placement Agent”) for the Company on a “reasonable best efforts” basis in connection with the Offering. The Company entered into a Placement Agency Agreement, dated as of January 29, 2021, by and between the Company and the Placement Agent (the “Placement Agency Agreement”). Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of 7% of the gross proceeds paid to the Company for the securities or $420,000, and reimbursement for accountable legal expenses incurred by it in connection with the Offering of $35,000. The shares of Common Stock sold in the Offering were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251645) (the “Registration Statement”), which was initially filed with the Securities and Exchange Commission on December 23, 2020 and was declared effective on December 29, 2020. The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement. In addition, such representations, warranties, and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement incorporated by reference in this filing only to provide investors with information regarding the terms of the transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties, and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures. The foregoing descriptions of the Purchase Agreement and the Placement Agency Agreement are not complete and are qualified in their entireties by reference to the full text of the Purchase Agreement and the Placement Agency Agreement, a copy of each of which is filed as Exhibit 10.1 and Exhibit 1.1, respectively, to the Company’s Current Report on Form 8-K as field on January 29, 2021 and each is incorporated by reference herein. Stock options: The 2016 Plan, which replaces the 2011 Plan, authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of January 1, 2022 and January 2, 2021, 90,000 and 78,000, respectively, options were outstanding under the 2016 Plan. The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of January 1, 2022 and January 2, 2021, 27,500 and 35,900 options, respectively, were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan. The following table summarizes stock option activity for the fiscal years ended January 1, 2022, and January 2, 2021 (Aggregate Intrinsic Value in $000's):
|  | Options |  |  | Weighted Average Exercise |  |  | Aggregate Intrinsic |  |  | Weighted Average Remaining Contractual |
|  | Outstanding |  |  | Price |  |  | Value |  |  | Life |
Outstanding at December 28, 2019 |  |  | 44,400 |  |  | $ | 13.31 |  |  | $ | — |  |  |  | 3.0 |
Cancelled/expired |  |  | (4,500 | ) |  |  | 9.45 |  |  |  |  |  |  |
Granted |  |  | 74,000 |  |  |  | 3.84 |  |  |  |  |  |  |
Outstanding at January 2, 2021 |  |  | 113,900 |  |  |  | 11.97 |  |  |  | 78 |  |  |  | 7.0 |
Granted |  |  | 38,000 |  |  |  | 8.16 |  |  |  |  |  |  |
Exercised |  |  | (6,000 | ) |  |  | 4.32 |  |  |  |  |  |  |
Cancelled/expired |  |  | (28,400 | ) |  |  | 9.71 |  |  |  |  |  |  |
Outstanding at January 1, 2022 |  |  | 117,500 |  |  | $ | 7.16 |  |  | $ | 21 |  |  |  | 7.0 |
Exercisable at January 1, 2022 |  |  | 110,000 |  |  | $ | 7.10 |  |  | $ | 21 |  |  |  | 6.9 |
The exercise price for stock options outstanding and exercisable outstanding at January 1, 2022 is as follows:
Outstanding |  | Exercisable
Number of Options |  |  | Exercise Price ($) |  | Number of Options |  |  | Exercise Price ($)
| 13,500 |  |  | $17.35 to $23.45 |  |  | 13,500 |  |  | $17.35 to $23.45
| — |  |  | $11.10 to $15.00 |  |  | — |  |  | $11.10 to $15.00
| 38,000 |  |  | $5.70 to $9.90 |  |  | 30,500 |  |  | $5.70 to $9.90
| 66,000 |  |  | $3.54 to $5.25 |  |  | 66,000 |  |  | $3.54 to $5.25
| 117,500 |  |  |  |  |  | 110,000 |  |  |
The following table summarizes information about the Company’s non-vested shares outstanding as of January 1, 2022 and January 2, 2021:
Non-vested Shares |  | Number of Shares |
Non-vested at December 28, 2019 |  |  | — |
Granted |  |  | 74,000 |
Vested |  |  | (25,500 | )
Non-vested at January 2, 2021 |  |  | 48,500 |
Granted |  |  | 38,000 |
Exercised |  |  | (6,000 | )
Forfeited |  |  | (28,400 | )
Vested |  |  | (44,600 | )
Non-vested at January 1, 2022 |  |  | 7,500 |
The Company recognized share-based compensation expense related to stock options of approximately $303,000 and approximately $173,000 for the fiscal years ended January 1, 2022, and January 2, 2021, respectively. As of January 1, 2022, the Company had approximately $5,000 of unrecognized share-based compensation expense associated with stock option awards, which the company expects to recognize as compensation expense through June 2022. Warrants: As of January 2, 2021, there were none and 33,363 warrants outstanding to purchase 33,363 shares of common stock at a price of $3.40 per share. The warrants expired in November 2021, and, consequently, no warrants were outstanding as of January 1, 2022.

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration